Eli Lilly's New Program to Boost Employer GLP-1 Coverage
Your Job Might Finally Help You Pay for That Weight Loss Drug , Here's What Eli Lilly Just Changed
And why HR departments across the country are paying very close attention right now.
You've probably heard about Zepbound or Mounjaro by now. Maybe your doctor mentioned it. Maybe a friend lost 40 pounds on it and you're quietly wondering if it could work for you. But then you looked into it… and saw the price tag. Hundreds of dollars a month. Not covered by your work insurance. A hard "no" from your PBM , whatever that even is.
And you thought: of course.
Here's the thing though , that story is starting to change. Quietly, but meaningfully. Eli Lilly just launched a new program specifically designed to help employers cover obesity drugs for their workers. And it's a much bigger deal than the press releases make it sound.
Let me break it down for you like I'm explaining it to a friend over lunch.
First, Why Is This Such a Big Deal?
Obesity drugs , specifically GLP-1 medications like Zepbound (tirzepatide) , have been hailed as some of the most significant medical breakthroughs in decades. We're talking about drugs that can help people lose 15–20% of their body weight. They're linked to reduced risk of heart disease, stroke, sleep apnea, and over 200 other conditions.
But here's the gut punch: just 19% of employers with 200 or more workers are currently covering GLP-1s for weight loss, according to KFF's 2025 employer benefits health survey. That's it. One in five.
So most people who could genuinely benefit from these drugs? They're either paying out of pocket , which can be $300 to $500+ a month , or going without.
That's the gap Eli Lilly is now trying to close. From the employer side.
What Eli Lilly Actually Built (And Why It's Different)
Here's where it gets interesting.
Eli Lilly recently announced a "direct-to-employer" model that allows employers to bypass pharmacy benefit managers (PBMs) and purchase the drugs directly, starting in early 2026.
Okay , so what's a PBM and why does bypassing them matter?
Think of PBMs as the middlemen between your employer's insurance plan and the pharmacy. They negotiate drug prices and pocket rebates. But the problem is, plan sponsors often don't have a complete picture of how these middlemen work with drugmakers and insurers , and that opacity makes it hard to know if you're actually getting a fair deal. One benefits expert called it the "PBM black hole."
By going direct, employers get something they've been desperate for: clarity. Fixed pricing. Transparency. And real control over what they're offering their people.
The program offers flexibility around benefit design, a dedicated pharmacy network that makes it easier to understand and track costs, and third-party support organizations to help employers build out holistic weight management solutions.
That last part matters more than it sounds. Weight loss drugs work best when they're paired with lifestyle support , nutrition coaching, behavioral health tools, that kind of thing. Lilly seems to understand that.
Who's Involved? (The Partner Network)
Lilly didn't build this alone. They brought in a whole crew.
Lilly is partnering with Waltz Health, Ilant, 9amHealth, and Goodpath on its employer-focused offerings.
- Waltz Health handles the fixed-price purchasing model, helping employers access lower-cost drugs without all the PBM drama.
- 9amHealth launched what they're calling the "No Barriers Bundle" , a partnership that provides in-tandem access to Lilly's obesity drugs and 9amHealth's obesity care platform, creating an efficient and cost-effective way for employers to offer this care.
- Goodpath and Ilant round out the ecosystem with holistic wellness and clinical support.
"Employers want to do the right thing for their people, but rising healthcare costs and complexity have made obesity care coverage difficult to manage," said Paul Geevarghese from 9amHealth.
That quote? That's the whole tension in one sentence. Employers want to cover this stuff. They're just not sure how to do it without the costs spiraling out of control.
What Does This Mean for Drug Pricing?
This is where things get genuinely exciting , and a little complicated.
On the government side, Eli Lilly struck a deal with the U.S. government in November 2025 to expand access to Zepbound and orforglipron (its forthcoming once-daily obesity pill) for Medicare beneficiaries and self-pay patients.
Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound's multi-dose pen and for orforglipron, provided both receive FDA approval.
And for people paying cash? A Zepbound multidose pen through Lilly's direct-to-consumer channel will cost $299 for the lowest dose and $449 for additional doses , a $50 discount from the current self-pay option and similar to prices in Europe.
Now, employers on private insurance are watching all of this very closely. "Once you have publicity around a Medicare price, I think the demand for a price that is close to that level is going to be really high," said Caroline Pearson from the Peterson Health Technology Institute.
In other words: the Medicare deal is quietly putting pressure on the whole market to bring prices down. Including for employer-sponsored plans.
What's Coming Next: The Oral Pill Could Change Everything
There's one more piece of this puzzle that HR departments and employees should watch.
Lilly has an oral GLP-1 obesity drug called orforglipron that's awaiting FDA approval , expected around Q2 2026. Orforglipron is a once-daily tablet that can be taken at any time without restrictions on food or water intake, offering advantages for patients who may struggle with subcutaneous injections.
A pill. Instead of a weekly injection. That's a huge deal for adoption.
Lilly CEO Dave Ricks said Medicare coverage of obesity drugs could "change the game" for the upcoming pill launch, with 20 to 30 million Medicare beneficiaries potentially eligible for GLP-1 treatments.
If oral options gain traction , especially at lower price points , the conversation around employer coverage gets much easier to have.
What This Means for HR & Benefits Leaders
If you work in HR or benefits , or you're just someone who thinks hard about where their health insurance dollars go , here's the practical takeaway:
Employers who act now will be ahead. As Lilly put it: "Obesity care is the next frontier in employer health benefits. Companies that act now will lead the way, closing coverage gaps and building healthier, more resilient workforces."
That's a little bit of marketing language, sure. But the underlying point isn't wrong.
The business case for covering these drugs is getting stronger. Obesity is linked to higher healthcare costs across the board , more sick days, more chronic disease management, more hospitalizations. If a $300/month drug reduces those downstream costs... that math might actually work in an employer's favor.
What Employees Should Know Right Now
If you're an employee wondering whether your company might cover Zepbound or similar drugs, here's what to do:
- Talk to HR. Ask directly whether GLP-1s are covered in your plan , for weight loss specifically, not just diabetes. The distinction matters.
- Check LillyDirect. If your employer doesn't cover these drugs yet, Lilly's platform LillyDirect served over one million patients a month in 2025, providing telehealth access to obesity specialists with upfront pricing before payment.
- Stay tuned for 2026 updates. Both the employer program rollout and the potential FDA approval of orforglipron are expected to shift coverage conversations significantly this year.
- Know your eligibility. Coverage criteria vary. Under the government deal, eligibility includes people with obesity and diabetes, uncontrolled high blood pressure, severe obesity, prediabetes, or prior cardiovascular events like stroke.
For years, GLP-1 drugs existed in this frustrating middle ground , enormously effective, wildly expensive, and largely invisible to most insurance plans. Eli Lilly's direct-to-employer program, the government pricing deals, and the incoming oral pill represent a genuine attempt to dismantle that wall.
Will it be perfect? No. Will prices stay low? That's genuinely unclear. Will every employer jump on board immediately? Definitely not.
But the direction of travel is unmistakable. And for the 40+ million Americans living with obesity who've been priced out of medications that could genuinely help them , that direction matters.